Inhibition of juvenile myelomonocytic leukemia cell growth in vitro by farnesyltransferase inhibitors

Blood

Volumn 95, Issue 2, 2000, Pages 639-645

  Emanuel, Peter D ^a,b   Snyder, Richard C ^a   Wiley, Tonya ^a   Gopurala, Balaganesh ^a   Castleberry, Robert P ^a  

^a and Clinical Center   (United States)

^b O Neal Comprehensive Cancer Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [[2 [[2 [(2 AMINO 3 MERCAPTOPROPYL)AMINO] 3 METHYLPENTYL]OXY] 1 OXO 3 PHENYLPROPYL]AMINO] 4 (METHYLSULFONYL)BUTANOIC ACID ISOPROPYL ESTER; CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; ISOTRETINOIN; N [2 [2 (2 AMINO 3 MERCAPTOPROPYLAMINO) 3 METHYLPENTYLOXY] 3 PHENYLPROPIONYL]METHIONINE SULFONE METHYL ESTER; PROTEIN FARNESYLTRANSFERASE INHIBITOR;

ANIMAL MODEL; ARTICLE; CELL GROWTH; CONTROLLED STUDY; DOSE RESPONSE; GENE; GROWTH INHIBITION; MOUSE; MYELOMONOCYTIC LEUKEMIA; NONHUMAN; PRENYLATION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 0034651043     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.2.639     Document Type: Article

References (85)

1. Altman AJ, Palmer CG, Baehner RL Juvenile "chronic granulocytic leukemia": a panmyelopathy with prominent monocytic involvement and circulating monocyte colony-forming cells. Blood. 1974:43:341-350.
2. Castro-Malaspina H, Schaison G, Passe S, et al. Subacute and chronic myelomonocytic leukemia in children (juvenile CML): clinical and hématologie observations, and identification of prognostic factors. Cancer. 1983:54:675-686.
3. Emanuel PD, Shannon KM, Castleberry RP. Juvenile myelomonocytic leukemia: molecular understanding and prospects for therapy. Mol Med Today. 1996:2:468-475.
4. Niemeyer CM, Arico M, Basso G, et al. Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. Blood. 1997:89: 3534-3543.
5. Arico M, Biondi A. Pul C-H. Juvenile myelomonocytic leukemia. Blood. 1997:90:479-488.
6. Chan HS, Estrov Z, Weitzman SS, Freedman MH. The value of intensive combination chemotherapy for juvenile chronic myelogenous leukemia. J Clin Oncol. 1987:5:1960-1967.
7. Festa RS, Shende A, Lanzkowsky P. Juvenile chronic myelocytic leukemia: experience with intensive combination chemotherapy. Med Pediatr Oncol. 1990:18:311-316.
8. Passmore SJ, Hann IM, Stiller ÇA, et al. Pédiatrie myelodysplasia: a study of 68 children and a new prognostic scoring system. Blood. 1995:85:17421750.
9. Haste H, Kerndrup G, Yssing M, et al. Intensive chemotherapy in childhood myelodysplastic syndrome: a comparison with results in acute myeloid leukemia. Leukemia. 1996:10:1269-1273.
10. Lilleyman JS, Harrison JF, Black JA. Treatment of juvenile chronic myeloid leukemia with sequential subcutaneous cytarabine and oral mercaptopurine. Blood. 1977:49:559-562.
11. Thomas WJ, North RB, Poplack DG, Slease RB, Duval-Arnold B. Chronic myelomonocytic leukemia in childhood. Am JHematol. 1981;10:181-194.
12. Castleberry RP, Emanuel PD, Zuckerman KS, et al. A pilot study of isotretinoin in the treatment of juvenile chronic myelogenous leukemia. N Engl J Med. 1994:331:1680-1684.
13. Castleberry RP, Chang M, Maybee D, Emanuel PD. A phase II study of 13-cis retinoic acid (CRA) in juvenile myelomonocytic leukemia (JMML): a Pédiatrie Oncology Group (POG) study [abstract]. Blood. 1997;90:346a.
14. Sanders JE, Buckner CD, Thomas ED, et al. AIlogeneic marrow transplantation for children with juvenile chronic myelogenous leukemia. Blood. 1988:71:1144-1146.
15. Smith FO, Sanders JE, Robertson KA, Gooley T, Sievers EL. Allogeneic marrow transplantation for children with juvenile chronic myelogenous leukemia [abstract]. Blood. 1994;84:201a.
16. Wagner JE, Broxmeyer HE, Byrd RL, et al. Transplantation of umbilical cord blood after myeloablative therapy: analysis of engraftment. Blood 1992; 79:1874-1881.
17. Locate!!! F, Niemeyer C, Angelucci E. et al. Allogeneic bone marrow transplantation for chronic . v myelomonocytic leukemia in childhood: a report from the European working group on myelodysplastic syndrome in childhood. J Clin Oncol. 1997;15:566-573.
18. Emanuel PD, Bates LJ, Castleberry RP, Gualtieri RJ, Zuckerman KS. Selective hypersensitivity to granulocyte-macrophage colony-stimulating factor by juvenile chronic myeloid leukemia hematopoietic progenitors. Blood. 1991;77:925-929.
19. Lapidot T, Cohen A, Grunberger T, Dick J, Freedman MH. Aberrant growth properties of juvenile chronic myelogenous leukemia (JCML) CD34+ cells in vitro and in vivo using SCID mouse assays [abstract]. Blood. 1993;82:197a.
20. Cambier N, Menot ML, Fenaux P, Wattel E, Baruchel A, Chomienne C. GM-CSF hypersensitivity in CD34+ purified cells in juvenile and adult chronic myelomonocytic leukemia: effect of retinoids [abstract]. Blood. 1995;86:791a.
21. Bos JL. Ras oncogenes in human cancer: a review. Cancer Res. 1989;49:4682-4689.
22. Satoh T, Nakafuku M, Miyajima A, Kaziro Y. Involvement of ras p21 protein in signal transduction pathways from interieukin 2, interieukin 3, and granulocyte/macrophage colony-stimulating factor, but not from interieukin 4. Proc Natl Acad Sei U S A. 1991 ;88:3314-3318.
23. Rodenhuis S. Ras and human tumors. Semin Cancer Biol. 1992;3:241-247.
24. Boguski MS, McCormick F. Proteins regulating Ras and its relatives. Nature. 1993:366:643-654.
25. Neubauer A, Shannon KM, Liu E. Mutations of the ras proto-oncogenes in childhood monosomy 7. Blood. 1991:77:594-598.
26. Lubber! M, Mirro J Jr, Kitchingman G, et al. Prevalence of N-ras mutations in children with myelodysplastic syndromes and acute myeloid leukemia. Oncogene. 1992;7:263-268.
27. Miyauchi J, Asada M, Sasaki M, Tsunematsu Y, Kojima S, Mizutani S. Mutations of the N-ras gene in juvenile chronic myelogenous leukemia. Blood. 1994;83:2248-2254.
28. Kalra R, Paderanga D, Oison K, Shannon KM. Genetic analysis is consistent with the hypothesis that NF1 limits myeloid cell growth through p21ras. Blood. 1994:84:3435-3439.
29. Bourne HR, Sanders DA, McCormick F. The GTPase superfamily: a conserved switch for diverse cell functions. Nature. 1990:348:125-129.
30. Bourne HR, Sanders DA, McCormick F. The GTPase superfamily: conserved structure and molecular mechanism. Nature. 1991;349:117-127.
31. Hall A. The cellular functions of small GTP-binding proteins. Science. 1990:249:635-640.
32. Bader JL, Miller RW. Neurofibromatosis and childhood leukemias. J Pediatr. 1978:92:925-929.
33. Gadner H, Haas OA. Experience in pédiatrie myf elodysplastic syndromes. Hematol Clin North Am. 1992;6:655-672.
34. Shannon KM, Watteson J, Johnson P, et al. Monosomy 7 myeloproliferative disease in children with neurofibromatosis, type 1: epidemiology and molecular analysis. Blood. 1992;79: 1311-1318.
35. Shannon KM, O'Connell P, Martin GA, et al. Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders. N Engt J Med. 1994;330: 597-601.
36. Brodeur GM. The NF1 gene in myelopoiesis and childhood myelodysplastic syndromes [editorial]. N Engl J Med. 1994;330:637-639.
37. Mites DK, Freedman MH, Stephens K, et al. Patterns of hematopoietic lineage involvement in children with neurofibromatosis type 1 and malignant myeloid disorders. Blood. 1996;8S:43144320.
38. Side L/Tayor B, Cayouette M, et al. Homozygous iriactivâtibn of the NF1 gene in bone marrow cells from children with neurofibromatosis type 1 and malignant myeloid disorders. N Engl J Med. 1997;336:1713-1720.
39. Side LE, Emanuel PD, Taylor B, et al. Mutations of the WF7 gene in children with juvenile myelomonocytic leukemia without clinical evidence of neurofibromatosis, type 1. Blood. 1998:92:267272.
40. Jacks T, Shin TS, Schmitt EM, Bronson RT, Bernards A, Weinberg RA. Tumour predisposition in mice heterozygous for a targeted mutation in Nf1. Nat Genet. 1994;7:353-361.
41. Largaespada DA. Brannan CI, Jenkins NA, Copeland NG. N! 1 deficiency causes Ras-mediated granulocyte/macrophage colony stimluating factor hypersensitiviry and chronic myeloid leukaemia. Nat Genet. 1996:12:137-143.
42. Bollag G, Clapp DW, Shih S, et al. Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nat Genet. 1996:2:144-148.
43. Zhang Y, Vik TA, Ryder JW, et al. Nf 1 regulates hematopoietic progenitor cell growth and Ras signaling in response to multiple cytokines. J Exp Med. 1998:87:1893-1902.
44. Birnbaum R, O'Marcaigh A, Wardak Z, et al. Interaction between NF1 and GMCSF in leukemogenesis and hematopoietic engraftment [abstract]. Blood. 1997;90:411a.
45. Emanuel PD, Bates U, Zhu S-W, Castleberry RP, Gualtieri RJ, Zuckerman KS. The role of monocyte-derived hemopoietic growth factors in the regulation of myeloproliferation in juvenile chronic myelogenous leukemia. Exp Hematol. 1991;19: 1017-1024.
46. Iversen PO, Hart PH, Bonder CS, Lopez AF. Interteukin (IL)-10, but not IL-4 or IL-13, inhibits cytokine production and growth in juvenile myelomonocytic leukemia cells. Cancer Res. 1997;57: 476-480.
47. Hercus TR, Bagley CJ, Cambareri B, et al. Specific human granulocyte-macrophage colonystimulating factor antagonists. Proc Natl Acad Sei USA. 1994:91:5838-5842.
48. Iversen PO, To LB, Lopez AF. Apoptosis of hemopoietic cells by the human granulocyte-macrophage colony-stimulating factor mutant E21R. Proc Natl Acad Sei U S A. 1996:93:2785-2789.
49. Iversen PO, Lewis ID, Turczynowicz S, et al. Inhibition of granulocyte-macrophage colony-stimulating factor prevents dissemination and induces remission of juvenile myelomonocytic leukemia in engrafted immunodeficient mice. Blood. 1997;90: 4910-4917.
50. Perentesis JP, Waddick KG, Bendel AE, et al. Induction of apoptosis in multidrug-resistant and radiation-resistant acute myeloid leukemia cells by a recombinant fusion toxin directed against the human granulocyte macrophage colony-stimulating factor receptor. Clin Cancer Res. 1997:3:347355.
51. Frankel AE, Hall PD, Burbage C, et al. Modulation of the apoptotic response of human myeloid leukemia cells to a diphtheria toxin granulocyte-macrophage colony-stimulating factor fusion protein. Blood. 1997:90:3654-3661.
52. Frankel AE, Lilly M, Kreitman R, et al. Diphtheria toxin fused to granulocyte-macrophage colonystimulating factor is toxic to blasts from patients with juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia. Blood. 1998; 92:4279-4286.
53. Willumsen BM, Morris K, Papageorge AG, Hubbert NL, Lowy DR. Harvey murine sarcoma virus p21 ras protein: biological and biochemical signficance ol the cysteine nearest the carboxy terminus. EMBO J. 1984;3:2581-2585.
54. Hancock JF, Magee AI, Childs JE, Marshall CJ. All Ras proteins are polyisoprenylated but only some are palmitoylated. Cell. 1989:57:1167-1177.
55. Jackson JH, Cochrane CG, Bourne JR. Solski PA, Buss JE, Der CJ. Farnesol modification of Kirsten-ras exon 4B protein is essential for transformation. Proc Natl Acad Sei USA. 1990;7: 3042-3046.
56. Kalo K, Cox AD, Hisaka MM, Graham SM, Buss JE, Der CJ. Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity. Proc Natl Acad Sei USA. 1992;89:6403-6407.
57. Newman CMH, Magee AI. Posttranslational processing of the ras superfamily of small GTP-binding proteins. Biochim Biophys Acta. 1993;1155: 79-96.
58. Gibbs JB, Oliff A, Kohl NE. Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic. Cell. 1994;77:175-178.
59. Kohl NE, Mosser SD, deSolams SJ, et al. Selective inhibition of ras-dependent transformation by a famesyltransferase inhibitor. Science. 1993; 260:1934-1937.
60. James GL, Goldstein JL, Brown MS, et al. Benzodiazepine peptidomimetics: potent inhibitors of ras farnesylation in animal cells. Science. 1993; 260:1937-1942.
61. Kohl NE, Wilson FR, Mosser SD, et al. Protein famesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice. Proc Natl AcadSciUSA. 1994:91:9141-9145.
62. Kohl NE, Omer CA, Conner MW, et al. Inhibition of famesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat Med. 1995:1:792-797.
63. Sepp-Lorenzino L, Ma Z, Rands E, et al. A peptidomimetic inhibitor of farnesyl: protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. Cancer Res. 1995:55:5302-5309.
64. Kohl NE, Conner MW, Gibbs JB, Graham SL, Hartman GD, Oliff A. Development of inhibitors of protein farnesylation as potential chemotherapeutic agents. J Cell Biochem. 1995;22(suppl):145150.
65. Gibbs JB, Oliff A. The potential of famesyltransferase inhibitors as cancer chemotherapeutics. Annu RevPharmacolToxicol. 1997:37:143-166.
66. Mangues R, Corral T, Kohl NE, et al. Antitumor effect of a farnesyl protein transferase inhibitor in mammary and lymphoid tumors overexpressing N-ras in transgenic mice. Cancer Res. 1998;58: 1253-1259.
67. Bartington RE, Subter MA, Rands E, et al. A favnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis. Mol Cell Biol. 1998:18:85-92.
68. Norgaard P, Law B, Joseph H, et al. Treatment with farnesyl-protein transferase inhibitor induces regression of mammary tumors in transforming growth factor (TGF) a and TGFo/neu transgenic mice by inhibition of mitogenic activity and induction of apoptosis. Clin Cancer Res. 1999:5:35-42.
69. Van N, Ricca C, Fletcher J, Glover T, Seizinger BR, Manne V. Famesyltransferase inhibitors block the neurofibromatosis type I (NF1) malignant phenotype. Cancer Res. 1995:55:35693575.
70. Kim HA, Ling B, Ratner N. Nf 1 -deficient mouse Schwann cells are angiogenic and invasive and can be induced to hyperproliferate: reversion of some phenotypes by an inhibitor of farnesyl protein transferase. Mol Cell Biol. 1997; 17:862-872.
71. Niemeyer CM, Fenu S, Hasle H, Mann G, Stary J, van Wering E. Differentiating juvenile myelomonocytic leukemia from infectious disease [response]. Blood. 198:91:365.
72. Gualtieri RJ, Castleberry RP, Gibbons J, et al. Cell culture studies and oncogene expression in juvenile chronic myelogenous leukemia. Exp Her'- matol. 1988:16:613-619.
73. Gualtieri RJ, Emanuel PD, Zuckerman KS, et al. Granulocyte-macrophage colony-stimulating factor is an endogenous regulator of cell proliferation in juvenile chronic myelogenous leukemia. Blood. 1989;74:2360-2367.
74. James GL, Goldstein JL, Brown MS. Polylysine and CVIM sequences of K-RasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro. J Biol Chem. 1995:270:6221-6226.
75. v12 proteins to famesyltransferase Inhibitors in Rat1 cells. Proc Natl Acad Sei USA. 1996; 93:4454-4458.
76. Whyte DB. Kirschmeieer P, Hockenberry TN, Nunez-Oliva I, James L. K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J Biol Chem. 1997;272: 14.45&-14,464.
77. Rowell CA, Kowalczyk JJ, Lewis MD, Garcia AM. Direct demonstration of geranylgeranylation and famesylation of Ki-Ras In vivo. J Biol Chem. 1997;272:14,093-14,097.
78. Prendergast GC, Davide JP, deSolms SJ, et al. Famesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton. Mol Cell Biol. 1994;14: 4193-4202.
79. Lebowitz PF, Davide JP, Prendergast GC. Evi dence that famesyl-transferase inhibitors suppress Ras transformation by interfering with Rho activity. Mol Cell Biol. 1995;15:6613-6622.
80. Lebowitz PF, Casey PJ, Prendergast GC, Thissen JA. Farnesyl-transferase inhibitors alter the prenylation and growth-stimulation function of RhoB. J Biol Chem. 1997;272:15,591-15,594.
81. Du W, Lebowitz PF, Prendergast GC. Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB. Mol Cell Biol. 1999:19:1831-1840.
82. Choy E, Chiu VK, Silletti J, et al. Endomembrane trafficking of Ras: the CAAX motif targets proteins to the ER and Golgi. Cell. 1989:98:69-80.
83. Mahgoub N, Taylor BR, Gratiot M, et al. In vitro and in vivo effects of a farnesyltransferase inhibitor on /Wf-deficient hematopoietic cells. Blood. 1999:94:2469-2476.
84. Iversen PO, Rodwell RL, Pitcher L, Taylor KM, Lopez AF. Inhibition of proliferation and induction of apoptosis in juvenile myelomonocytic leukemic cells by the granulocyte-macrophage colonystimulating factor analogue E21R. Blood. 1996; 88:2634-2639.
85. Snyder RC, Wiley T, Castleberry RC, Emanuel PD. Increased levels of the p85a regulatory subunit of phosphatidylinisitol 3-OH kinase in cell lysates of juvenile myeiomonocytic leukemia cells [abstract]. Blood. 1997;90:411a.